iCAD (NASDAQ:ICAD) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s What Happened

iCAD, Inc. (NASDAQ:ICAD)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.64 and traded as high as $3.85. iCAD shares last traded at $3.76, with a volume of 300,078 shares.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Wall Street Zen initiated coverage on shares of iCAD in a research note on Tuesday, May 20th. They issued a “sell” rating on the stock. Laidlaw reiterated a “hold” rating on shares of iCAD in a research note on Thursday, April 17th. BTIG Research downgraded shares of iCAD from a “buy” rating to a “neutral” rating in a research note on Wednesday, April 16th. Finally, Craig Hallum downgraded shares of iCAD from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 16th.

iCAD Price Performance

The stock’s 50 day simple moving average is $3.29 and its two-hundred day simple moving average is $2.64. The stock has a market cap of $103.29 million, a price-to-earnings ratio of -28.92 and a beta of 1.38.

iCAD (NASDAQ:ICAD) last issued its quarterly earnings data on Tuesday, May 13th. The technology company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.04. The company had revenue of $4.87 million during the quarter, compared to analysts’ expectations of $4.54 million. iCAD had a negative return on equity of 15.65% and a negative net margin of 17.81%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Thompson Davis & CO. Inc. bought a new position in shares of iCAD during the fourth quarter valued at $31,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of iCAD during the first quarter valued at $40,000. Goldman Sachs Group Inc. bought a new position in shares of iCAD during the first quarter valued at $44,000. PKS Advisory Services LLC bought a new position in shares of iCAD during the fourth quarter valued at $53,000. Finally, Cubist Systematic Strategies LLC bought a new position in shares of iCAD during the first quarter valued at $71,000. 24.61% of the stock is owned by institutional investors.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.